###begin article-title 0
Could a defective epithelial sodium channel lead to bronchiectasis
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 323 328 323 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 435 444 435 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC&#946; </italic>
###xml 404 419 <span type="species:ncbi:10090">transgenic mice</span>
Bronchiectasis is defined as a permanent dilation of the airways arising from chronic bronchial inflammation/infection. In 50% of cases, no etiology can be identified. Recently, the role of the epithelial sodium channel ENaC has been pointed out in the pathophysiology of cystic fibrosis, a disease due to mutations in the CFTR gene and causing bronchiectasis in the airways. Moreover, it was found that transgenic mice overexpressing ENaCbeta present cystic fibrosis-like lung disease symptoms. Our aim was to evaluate if a defective ENaC protein could be involved in the development of bronchiectasis.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 24 33 24 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC&#946; </italic>
###xml 37 43 34 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#947; </italic>
###xml 146 150 139 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR</italic>
###xml 55 63 <span type="species:ncbi:9606">patients</span>
###xml 165 173 <span type="species:ncbi:9606">patients</span>
We extensively analysed ENaCbeta and gamma genes in 55 patients with idiopathic bronchiectasis and without two mutations in the coding regions of CFTR. Thirty-eight patients presented functional abnormalities suggesting impaired sodium transport (abnormal sweat chloride concentration or nasal potential difference measurement), and 17 had no such evidence.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 52 61 52 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC&#946; </italic>
###xml 65 71 62 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#947; </italic>
###xml 162 171 155 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC&#946; </italic>
###xml 205 214 195 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC&#947;</italic>
###xml 353 358 339 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 488 493 474 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 617 622 603 608 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC </italic>
###xml 243 251 <span type="species:ncbi:9606">patients</span>
###xml 311 319 <span type="species:ncbi:9606">patients</span>
###xml 471 479 <span type="species:ncbi:9606">patients</span>
###xml 533 541 <span type="species:ncbi:9606">patients</span>
###xml 575 583 <span type="species:ncbi:9606">patients</span>
###xml 597 605 <span type="species:ncbi:9606">patients</span>
Sequencing of the exons and flanking introns of the ENaCbeta and gamma gene identified five different amino-acid changes (p.Ser82Cys, p.Pro369Thr, p.Asn288Ser in ENaCbeta ; and p.Gly183Ser, p.Glu197Lys in ENaCgamma) in heterozygous state in 8 patients. The p.Ser82Cys amino-acid change was found in 3 unrelated patients who were also heterozygous for a CFTR mutation or variant (1 p.F508del, 1 IVS8-5T, and 1 IVS8-5T:1716G>A (p.E528E)). The other mutations were found in patients without CFTR mutation, the p.Glu197Lys mutation in 2 patients and the other variants in single patients. Among the 8 patients bearing an ENaC mutation, 5 had functional abnormalities suggesting impaired sodium transport.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 45 54 45 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC&#946; </italic>
###xml 58 64 55 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#947; </italic>
###xml 192 206 185 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC&#946;/CFTR </italic>
###xml 151 159 <span type="species:ncbi:9606">patients</span>
Our results suggest that several variants in ENaCbeta and gamma genes might be deleterious for ENaC function and lead to bronchiectasis, especially in patients who are trans-heterozygotes for ENaCbeta/CFTR mutations or variants.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 705 706 705 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 232 240 <span type="species:ncbi:9606">patients</span>
Bronchiectasis is an abnormal dilation of bronchi due to the destruction of their walls. The main symptoms associated with bronchiectasis are chronic cough, purulent sputum and recurrent lower respiratory tract infections, and most patients show a varying degree of airflow obstruction. In approximately 50% of cases, causative factors are identified such as childhood infection, immune defects, allergic bronchopulmonary aspergillosis, aspiration of irritants, cystic fibrosis, primary ciliary dyskinesia, rheumatoid arthritis, other connective tissue disorders, ulcerative colitis, and alpha-1 antitrypsin deficiency. The remaining 50% of cases without identified etiology are classified as idiopathic [1].
###end p 11
###begin p 12
###xml 437 438 415 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 439 440 417 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 622 623 600 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 658 663 636 641 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC </italic>
###xml 914 915 885 886 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1149 1150 1109 1110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 626 631 <span type="species:ncbi:9606">Human</span>
###xml 1162 1170 <span type="species:ncbi:9606">patients</span>
The amiloride-sensitive epithelial sodium channel (ENaC) allows passive transport of sodium into the cells. It is expressed in epithelial cells lining the renal tubule, the respiratory airways and alveoli, the distal colon and the duct of several exocrine glands, such as salivary and sweat glands. ENaC is composed of three subunits (alpha, beta and gamma) in the proposed stoichiometry 2alpha :1beta :1gamma, or 3alpha :3beta :3gamma [2,3]. Each ENaC subunit activity may be regulated by other proteins such as CFTR (Cystic Fibrosis Transmembrane conductance Regulator) which is the protein involved in cystic fibrosis [4]. Human clinical disorders due to ENaC mutations are a rare occurrence. However, they have been well described. Liddle's syndrome (OMIM 177200), an autosomal dominant form of volume-expanded low-renin hypertension is caused by gain-of-function mutations in the beta or gamma ENaC subunits [5]. In contrast, loss-of-function mutations in the alpha, beta or gamma ENaC subunits have been found in autosomal recessive pseudohypoaldosteronisme type I (PHA-I) (OMIM 264350) with salt wasting, hyperkalemia and metabolic acidosis [6]. In PHA-I patients, there is also a defective sodium transport in the sweat glands that causes elevated sweat chloride and sodium concentrations. Hence, as sweat testing is the standard diagnostic test for cystic fibrosis, PHA-I is a classic differential diagnosis of elevated sweat chloride concentration, although usually readily distinguishable from cystic fibrosis.
###end p 12
###begin p 13
###xml 236 237 232 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 404 405 389 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 636 637 621 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 863 865 848 850 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 972 974 957 959 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1104 1106 1089 1091 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 85 89 <span type="species:ncbi:10090">mice</span>
###xml 123 127 <span type="species:ncbi:10090">mice</span>
###xml 250 254 <span type="species:ncbi:10090">mice</span>
###xml 411 417 <span type="species:ncbi:9606">humans</span>
###xml 703 711 <span type="species:ncbi:9606">patients</span>
###xml 878 886 <span type="species:ncbi:9606">patients</span>
###xml 988 996 <span type="species:ncbi:9606">patients</span>
Recently, the ENaC channel has been shown to play a critical role in lung and airway mice physiology : ENaCalpha knock-out mice died shortly after birth of respiratory failure due to an inability to clear fluid from the alveolar space [7]. Moreover, mice overexpressing ENaCbeta subunit, but not alpha or gamma, developed cystic-fibrosis-like disease with mucus obstruction and poor bacterial clearance [8]. In humans, cystic fibrosis disease in the airways is linked to the combined defects of failure to secrete chloride and of accelerated sodium transport resulting from the absence of ENaC inhibition by the defective CFTR protein [9]. Moreover, some respiratory abnormalities have been reported in patients with clinical disorders due to ENaC mutations. Hence, in Liddle's syndrome, an increased sodium channel activity in the nasal epithelium was observed [10]. In PHA-I, patients frequently exhibit respiratory tract disease, especially up to the age of 5-6 years [11] and in some patients, a defect in nasal epithelial sodium transport has been described with an excess of airway surface liquid [12].
###end p 13
###begin p 14
###xml 252 257 241 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 328 338 317 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC&#945; </italic>
###xml 350 358 335 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC&#946;</italic>
###xml 411 420 393 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC&#946; </italic>
###xml 431 433 410 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 578 587 557 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC&#946; </italic>
###xml 591 601 567 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC&#947; </italic>
###xml 707 716 679 685 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC&#946; </italic>
###xml 719 725 688 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#947; </italic>
###xml 812 817 777 782 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 887 896 852 858 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC&#946; </italic>
###xml 899 905 861 863 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#947; </italic>
###xml 146 154 <span type="species:ncbi:9606">patients</span>
###xml 164 172 <span type="species:ncbi:9606">patients</span>
###xml 287 295 <span type="species:ncbi:9606">patients</span>
###xml 613 621 <span type="species:ncbi:9606">patients</span>
###xml 670 678 <span type="species:ncbi:9606">patients</span>
###xml 770 778 <span type="species:ncbi:9606">patients</span>
###xml 850 858 <span type="species:ncbi:9606">patients</span>
Recently, sequencing of the exons and flanking introns of the genes encoding the alpha, beta, and gamma subunits of ENaC in twenty non-classic CF patients, that is patients with bronchiectasis and elevated sweat chloride concentrations but without two CFTR mutations, identified in four patients five missense mutations (one in ENaCalpha and four in ENaCbeta) and one splicing mutation in the 3' splice site of ENaCbeta intron 12 [13]. Our aim was to evaluate if a defective ENaC protein could be involved in the development of bronchiectasis. To do so, we extensively analysed ENaCbeta and ENaCgamma genes in 55 patients with idiopathic bronchiectasis and identified 8 patients bearing one mutation in the ENaCbeta or gamma genes. One mutation was found in 3 unrelated patients who were also heterozygous for a CFTR mutation or variant. Moreover, 5 patients bearing one mutation in the ENaCbeta or gamma genes had functional abnormalities in the nasal epithelium or in the sweat glands suggesting impaired sodium transport.
###end p 14
###begin title 15
###xml 13 21 <span type="species:ncbi:9606">Patients</span>
Material and Patients
###end title 15
###begin title 16
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and controls
###end title 16
###begin p 17
###xml 351 353 351 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 389 394 389 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 553 558 553 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 872 894 872 894 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Aspergillus fumigatus </italic>
###xml 14 22 <span type="species:ncbi:9606">patients</span>
###xml 27 30 <span type="species:ncbi:9606">men</span>
###xml 38 43 <span type="species:ncbi:9606">women</span>
###xml 522 529 <span type="species:ncbi:9606">patient</span>
###xml 872 893 <span type="species:ncbi:5085">Aspergillus fumigatus</span>
###xml 1090 1097 <span type="species:ncbi:9606">patient</span>
###xml 1196 1204 <span type="species:ncbi:9606">patients</span>
We studied 55 patients (13 men and 42 women) with diffuse idiopathic bronchiectasis recruited from the respiratory physiology department of Cochin University Hospital, Paris, France. Bronchiectasis was diagnosed on chronic cough with purulent sputum and bronchial dilation involving more than one lobe on high-resolution computed tomography scanning [14]. A complete genomic screening for CFTR gene mutations by denaturing high performance liquid chromatography (DHPLC) and direct sequencing analysis was performed and no patient carried two pathogenic CFTR mutations. No other known etiology of bronchiectasis was found such as infectious causes, immune disorders, primary ciliary dyskinesia or chronic rheumatic inflammatory conditions as assessed by : complete medical history, blood investigations (serum protein electrophoresis, immunoglobulins (Ig), IgG subclasses, Aspergillus fumigatus radioallergosorbent (RAST), autoantibodies including rheumatoid factor, alpha1-antitrypsin) and nasal mucociliary clearance (measured by the saccharin test and nasal nitric oxide measurement). No patient had a history of salt wasting or a familial history of respiratory or metabolic diseases, and all patients were normotensive.
###end p 17
###begin p 18
###xml 427 429 427 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 503 505 503 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 738 740 738 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 867 869 867 869 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 986 988 986 988 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1335 1337 1335 1337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 62 70 <span type="species:ncbi:9606">patients</span>
###xml 520 528 <span type="species:ncbi:9606">patients</span>
###xml 545 553 <span type="species:ncbi:9606">patients</span>
###xml 611 619 <span type="species:ncbi:9606">patients</span>
###xml 787 795 <span type="species:ncbi:9606">patients</span>
###xml 816 824 <span type="species:ncbi:9606">patients</span>
###xml 1352 1360 <span type="species:ncbi:9606">patients</span>
###xml 1371 1379 <span type="species:ncbi:9606">patients</span>
Sweat test and nasal PD measurements were performed on the 55 patients in order to study sodium transport in the sweat glands and in the nasal epithelium. Nasal PD measurements were performed by using 2 silver/silver chloride electrodes connected to a high impedance voltmeter, one electrode being in contact with the inferior surface of the nasal inferior turbinate and the other, with the subcutaneous tissue of the forearm [15]. The basal nasal PD reflects the basal rate of nasal sodium absorption [15]. Group 1 (38 patients) was defined as patients who had either abnormal sweat chloride concentration (13 patients) of more than 40 mmol per liter in a sample of at least 75 mg of sweat induced by means of pilocarpine iontophoresis [16] or abnormal basal nasal PD (> |-30| mV in 14 patients or < |-10| mV in 11 patients) measured as described by Knowles et al. [15]. When the basal nasal PD was above |-30| mV, a pharmacological study was performed as described by Knowles et al. [15]. This pharmacological study allows to explore each component of nasal epithelial ion transport by using various pharmacological agents such as amiloride, a blocker of epithelial sodium channel, a low chloride solution which allows the determination of basal chloride conductance and isoproterenol which explores CFTR-related chloride transport [15]. Group 2 (17 patients) included patients with no evidence of impaired sodium transport as evaluated by normal sweat chloride concentrations (< 40 mmol/L) and normal basal PD (>/= |-10| and </= |-30| mV). Values of forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) were determined on the day of nasal PD measurements and expressed as percentages of predicted values.
###end p 18
###begin p 19
###xml 106 111 106 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 115 120 115 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC </italic>
A control group comprising 50 subjects of Caucasian origin with no pulmonary disease were studied for the CFTR and ENaC genes. All individuals gave written informed consent.
###end p 19
###begin title 20
Methods
###end title 20
###begin p 21
###xml 210 219 210 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC&#946; </italic>
###xml 223 233 220 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC&#947; </italic>
###xml 323 325 312 314 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 367 368 356 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 360 365 <span type="species:ncbi:10090">mouse</span>
Genomic DNA was extracted from peripheral blood lymphocytes according to standard protocols and was used to amplify the thirteen exons (twelve coding exons; exon 2 to exon 13) and the flanking sequences of the ENaCbeta and ENaCgamma genes. Because lung-specific overexpression of ENaCalpha was not associated with raised Na+ transport rates or lung disease in mouse [8], we did not study this subunit. All samples were collected after a written informed consent was obtained.
###end p 21
###begin p 22
###xml 10 19 10 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC&#946; </italic>
###xml 23 33 20 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC&#947; </italic>
###xml 263 286 256 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC&#946; and ENaC&#947; </italic>
###xml 376 378 362 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 475 476 460 461 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1189 1191 1155 1157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1499 1500 1465 1466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 4 9 <span type="species:ncbi:9606">human</span>
###xml 926 934 <span type="species:ncbi:9606">patients</span>
The human ENaCbeta and ENaCgamma genes are located on chromosome 16, composed of thirteen exons and encode a 640 and 649 aminoacid protein, respectively. The ATG start codon is located in exon 2 and the TGA stop codon is located in exon 13. The coding regions of ENaCbeta and ENaCgamma have been amplified in twelve fragments. Primer sequences have been previously described [17]. Reactions were performed in a volume of 50 mul containing 50 mM Tris-HCl (pH 8.4), 1.5 mM MgCL2, 200 muM of all four deoxynucleotides, 0.5 mM each of the primers, 2.5 units of Taq Polymerase (Gold, Perkin Elmer) and 100 ng template DNA. Forty cycles were then performed with denaturation for 30 sec at 72degreesC. The DNA synthesis step of the final cycle was extended to 7 min. For DHPLC analysis, the amplified DNA was heated at 94degreesC for 7 min, and at 55degreesC for 4 min to favour formation of heteroduplexes. Mutation analysis of the patients with idiopathic bronchiectasis was performed by using DHPLC (Wave DNA fragment analysis system, DNAsep column; Transgenomics). DHPLC conditions were chosen according to the Wavemaker program (Transgenomics, Santa Clara, CA, USA) as previously described [17]. PCR products were subjected to chromatography using appropriate temperatures and acetonitrile gradient at a flow rate of 0.9 ml/mn, and those showing an abnormal DHPLC profile were directly sequenced on an automated sequencer (ABI 3100, Applied Biosystems, USA) using the BigDye Terminator method (Figure 1).
###end p 22
###begin p 23
###xml 134 142 134 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC&#946;</italic>
###xml 316 325 313 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC&#946; </italic>
(A) Denaturing high performance liquid chromatography patterns of polymerase chain reaction products corresponding to exon 5 and 7 of ENaCbeta : DHPLC profile corresponding to normal exon sequence (control), and altered DHPLC because of a substitution. (B) Fluorescence sequence analysis of exon 5 and exon 7 of the ENaCbeta gene, using the forward primer. Arrows indicate position of the p.Asn288Ser and p.Pro369Thr mutations in exon 5 and 7, respectively.
###end p 23
###begin p 24
###xml 125 127 125 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
The influence of base substitutions on putative exonic splice element (ESE) sites was determined with the ESEfinder program [18].
###end p 24
###begin title 25
Statistics
###end title 25
###begin p 26
The Hardy-Weinberg equation tested allelic disequilibrium for the common polymorphisms. Comparison between subjects grouped on the basis of their phenotypes was accomplished by Fisher's exact test (two tailed) for categorical variables and by Mann-Whitney U test for continuous variables. P values below 0.05 were defined as significant.
###end p 26
###begin title 27
Results
###end title 27
###begin title 28
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 28
###begin p 29
###xml 155 156 155 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 251 256 251 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 683 688 683 688 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 4 12 <span type="species:ncbi:9606">patients</span>
###xml 51 59 <span type="species:ncbi:9606">patients</span>
###xml 90 98 <span type="species:ncbi:9606">patients</span>
###xml 109 116 <span type="species:ncbi:9606">patient</span>
###xml 139 146 <span type="species:ncbi:9606">patient</span>
###xml 199 207 <span type="species:ncbi:9606">patients</span>
###xml 230 238 <span type="species:ncbi:9606">patients</span>
###xml 292 300 <span type="species:ncbi:9606">patients</span>
###xml 479 487 <span type="species:ncbi:9606">patients</span>
All patients were caucasian europeans except for 4 patients who originated from Africa (2 patients), Asia (1 patient) and South America (1 patient). Table 1 shows the clinical characteristics of the patients. In both groups, some patients carried one CFTR mutation or variant : in Group 1, 5 patients were heterozygous for the p.F508del, 1 for the 2183AA>G mutation, 1 for the 4375-20G>A variant, 2 for the IVS8-5T allele and 3 for the c.1716G>A (p.E528E) variant. In Group 2, 2 patients were heterozygous for the p.F508del, 2 for the p.R117H-7T mutation, 3 for the IVS8-5T allele, and 1 for the c.1717G>A (p.E528E) variant. There was no statistical difference in the frequencies of CFTR mutations between the 2 groups.
###end p 29
###begin p 30
###xml 31 39 <span type="species:ncbi:9606">patients</span>
Main characteristics of the 55 patients with idiopathic bonchiectasis
###end p 30
###begin p 31
Results are expressed as mean +/- SEM; BMI : body mass index, FEV1 : forced expiratory volume in 1 second, PD : potential difference.
###end p 31
###begin title 32
###xml 17 22 17 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC </italic>
Screening of the ENaC gene
###end title 32
###begin p 33
###xml 47 56 47 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC&#946; </italic>
###xml 60 70 57 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC&#947; </italic>
###xml 296 305 289 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC&#946; </italic>
###xml 351 361 341 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC&#947; </italic>
###xml 143 151 <span type="species:ncbi:9606">patients</span>
All the exons and exon-intron junctions of the ENaCbeta and ENaCgamma gene were screened for mutations and/or polymorphisms by DHPLC in the 55 patients with bronchiectasis of unknown origin. DHPLC analysis revealed the absence of mutations or polymorphisms in exons 3, 4, 6, 9, 10, 11, 12 of the ENaCbeta gene and in exons 2, 5, 6, 7, 8 and 12 of the ENaCgamma gene.
###end p 33
###begin title 34
###xml 17 26 17 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC&#946; </italic>
Mutations in the ENaCbeta gene
###end title 34
###begin p 35
###xml 17 26 17 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC&#946; </italic>
###xml 214 215 211 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 282 284 279 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 629 631 626 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 315 323 <span type="species:ncbi:9606">patients</span>
###xml 411 418 <span type="species:ncbi:9606">patient</span>
###xml 495 500 <span type="species:ncbi:9606">human</span>
###xml 509 515 <span type="species:ncbi:9986">rabbit</span>
###xml 517 520 <span type="species:ncbi:10116">rat</span>
###xml 525 530 <span type="species:ncbi:10090">mouse</span>
###xml 613 618 <span type="species:ncbi:10090">mouse</span>
###xml 623 626 <span type="species:ncbi:10116">rat</span>
Screening of the ENaCbeta gene by DHPLC and direct sequencing revealed three different amino-acid changes : p.Ser82Cys c.245C>G in exon 2, p.Asn288Ser c.863A>G in exon 5 and p.Pro369Thr c.1105C>A in exon 7 (Figure 1). The p.Ser82Cys amino-acid change has been previously described [13] and was found in 3 unrelated patients. The two other mutations have not been previously described and were found each in one patient. The amino acids Ser82 and Asn288 are completely conserved in paralogues in human, canis, rabbit, rat and mouse. However, the amino acid Pro369 is not completely conserved in paralogues (Ala in mouse and rat) [19].
###end p 35
###begin title 36
###xml 57 66 57 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC&#946; </italic>
###xml 23 31 <span type="species:ncbi:9606">patients</span>
Characteristics of the patients bearing mutations in the ENaCbeta gene
###end title 36
###begin p 37
###xml 379 384 379 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 58 66 <span type="species:ncbi:9606">patients</span>
###xml 164 172 <span type="species:ncbi:9606">patients</span>
###xml 309 317 <span type="species:ncbi:9606">patients</span>
These three missense mutations were identified 4 times in patients from Group 1 (2 : p.Ser82Cys, 1 : p.Pro369Thr and 1 : p.Asn288Ser; 4/38; 10.5%) and only once in patients from Group 2 (p.Ser82Cys; 1/17; 5.9%). None of these mutations were found in the ethnically-matched control group. Interestingly, the 3 patients bearing the p.Ser82Cys mutation were also heterozygous for a CFTR mutation or variant (1 p.F508del, 1 IVS8-5T, and 1 IVS8-5T:1716G>A (p.E528E)).
###end p 37
###begin p 38
###xml 72 81 72 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC&#946; </italic>
###xml 105 106 102 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 357 379 352 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pseudomonas aeruginosa</italic>
###xml 32 40 <span type="species:ncbi:9606">patients</span>
###xml 357 379 <span type="species:ncbi:287">Pseudomonas aeruginosa</span>
###xml 384 392 <span type="species:ncbi:9606">patients</span>
###xml 517 524 <span type="species:ncbi:9606">patient</span>
###xml 619 626 <span type="species:ncbi:9606">patient</span>
The main characteristics of the patients bearing a missense mutation in ENaCbeta gene are shown in Table 2. All were caucasian europeans, except a 35-year old female who originated from South America. Most of them were quite elderly adults (>/= 60 years-old), all of them had a normal or subnormal respiratory function. None had a bronchial colonization by Pseudomonas aeruginosa. In patients from group 1, all but one had a normal or a very low basal nasal PD and a pharmacological study was not performed. The only patient with a high basal nasal PD in absolute value (- 43 mV) bore the mutation p.Pro369Thr. In this patient, the sweat chloride concentration was normal (22 mmol/L) and the PD response to pharmacological solutions was normal : it was reduced to - 22 mV with amiloride, a sodium channel inhibitor. A normal response was observed after perfusion of a low chloride solution (- 44 mV) and subsequently after perfusion of the beta-agonist isoproterenol which induces cAMP dependent chloride conductance (- 56 mV), showing a functional CFTR protein.
###end p 38
###begin p 39
###xml 100 109 100 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC&#946; </italic>
###xml 30 38 <span type="species:ncbi:9606">patients</span>
Main characteristics of the 5 patients with idiopathic bonchiectasis bearing a missense mutation in ENaCbeta gene
###end p 39
###begin p 40
F : female, M : male, BMI : body mass index, FEV1 : forced expiratory volume in 1 second, pred : predicted, PD : nasal potential difference.
###end p 40
###begin title 41
###xml 21 30 21 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC&#946; </italic>
Polymorphisms in the ENaCbeta gene
###end title 41
###begin p 42
###xml 290 298 <span type="species:ncbi:9606">patients</span>
###xml 439 447 <span type="species:ncbi:9606">patients</span>
###xml 527 535 <span type="species:ncbi:9606">patients</span>
Four silent polymorphisms (p.Pro93Pro c.279C>T in exon 2; p.Phe293Phe c.879C>T in exon 5; p.Pro407Pro in exon 8; and p.Asn629Asn in exon 13) and one nucleotide change in the noncoding region (c.IVS12-17C>T) were also found. The silent polymorphism p.Phe293Phe was observed in six unrelated patients (6/55; 11%) (6 in group 1 (15%) vs 0 in Group 2 (0%)) and the common polymorphism p.Pro93Pro was identified at the heterozygous state in 18 patients (18/55; 33%) (13 in Group 1 and 5 in Group 2) and at the homozygous state in 9 patients (9/55; 16%) (5 in Group 1 (13%) and 4 in Group 2 (23%)). The two other silent polymorphisms (p.Pro407Pro and p.Asn629Asn) were only observed once.
###end p 42
###begin title 43
###xml 17 27 17 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC&#947; </italic>
Mutations in the ENaCgamma gene
###end title 43
###begin p 44
###xml 17 26 17 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC&#947;</italic>
Screening of the ENaCgammagene by DHPLC and direct sequencing revealed two amino-acid changes (p.Gly183Ser c.547G>A in exon 3 and p.Glu197Lys c.591G>A in exon 3).
###end p 44
###begin title 45
###xml 57 67 57 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC&#947; </italic>
###xml 23 31 <span type="species:ncbi:9606">patients</span>
Characteristics of the patients bearing mutations in the ENaCgamma gene
###end title 45
###begin p 46
###xml 56 63 <span type="species:ncbi:9606">patient</span>
###xml 169 177 <span type="species:ncbi:9606">patients</span>
The p.Gly183Ser amino-acid change was found in a female patient from Group 1 who originated from Africa and the p.Glu197Lys amino-acid change was found in two unrelated patients from Group 2. None of these mutations were found in the ethnically-matched control group.
###end p 46
###begin p 47
###xml 72 81 72 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC&#947;</italic>
###xml 105 106 101 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 123 128 119 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 32 40 <span type="species:ncbi:9606">patients</span>
###xml 142 149 <span type="species:ncbi:9606">patient</span>
###xml 459 467 <span type="species:ncbi:9606">patients</span>
###xml 531 539 <span type="species:ncbi:9606">patients</span>
The main characteristics of the patients bearing a missense mutation in ENaCgammagene are shown in Table 3. None carried a CFTR mutation. The patient from Group 1 carrying the p.Gly183Ser mutation had normal sweat chloride concentrations (7 mmol/L), an abnormal basal nasal PD (- 39 mV) with normal response to amiloride (- 29 mV) and to low chloride solution (- 40 mV). No response was observed after perfusion with isoprenaline (- 40 mV). In Group 2, the 2 patients carrying the p.Glu197Lys were among the most severely affected patients of Group 2 with airway obstruction on pulmonary function tests.
###end p 47
###begin p 48
###xml 101 111 101 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC&#947; </italic>
###xml 30 38 <span type="species:ncbi:9606">patients</span>
Main characteristics of the 3 patients with idiopathic bronchiectasis bearing a missense mutation in ENaCgamma gene
###end p 48
###begin p 49
F : female, M : male, BMI : body mass index, FEV1 : forced expiratory volume in 1 second, pred : predicted, PD : nasal potential difference.
###end p 49
###begin title 50
###xml 21 31 21 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC&#947; </italic>
Polymorphisms in the ENaCgamma gene
###end title 50
###begin p 51
###xml 693 695 693 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 504 512 <span type="species:ncbi:9606">patients</span>
###xml 674 679 <span type="species:ncbi:9606">human</span>
###xml 838 846 <span type="species:ncbi:9606">patients</span>
###xml 1102 1110 <span type="species:ncbi:9606">patients</span>
Six silent polymorphisms (p.Tyr129Tyr c.387T>C in exon 3; p.Ser145Ser c.435C>T in exon 3; p.Ileu158Ileu c.474T>C in exon 3; p.Gly183Gly c.549C>T in exon 3; p.Ser212Ser c.636C>T in exon 4; p.Val492Val c.1476A>G in exon 12; p.Leu649Leu c.1947 C>G in exon 13) and five intronic sequence variations (c.IVS7+14A>G; IVS7+69A>G; c.1371+29T>C; c.1432-7G>A; c.1432-106A>G) were also found. The common polymorphisms p.Tyr129Tyr and p.Ileu158Ileu (also named rs4365290 and rs5735, respectively) were observed in 28 patients (28/55 i.e. 51%; 18 (47%) in Group 1 and 10 (59%) in Group 2) at the heterozygous state. In the ensembl database which provides accurate analysis of the current human genome data [20], these variants were observed at the heterozygous state in 54%. The common polymorphism p.Leu649Leu (also named rs5723) was identified in 18 patients (18/55 i.e. 33%; 12 (32%) in Group 1 and 6 (35%) in Group 2) and was in perfect linkage with the two intronic sequence variations c.1371+29T>C and c.1432-7G>A. The common polymorphism p.Ser212Ser (also named rs16977041) was only observed in two unrelated patients from Group 1 (2/55; 4%) and the two other silent mutations p.Ser145Ser and p.Val492Val were only observed once (both from Group 1; 2%). None of the intronic nucleotide changes altered the consensus splice sites, suggesting that they are common polymorphisms rather than disease-causing mutations.
###end p 51
###begin title 52
Discussion
###end title 52
###begin p 53
###xml 133 142 133 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC&#946; </italic>
###xml 145 155 142 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC&#947; </italic>
###xml 244 249 237 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 497 502 490 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC </italic>
###xml 628 633 621 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC </italic>
###xml 32 40 <span type="species:ncbi:9606">patients</span>
###xml 82 90 <span type="species:ncbi:9606">patients</span>
###xml 216 224 <span type="species:ncbi:9606">patients</span>
###xml 454 462 <span type="species:ncbi:9606">patients</span>
###xml 476 484 <span type="species:ncbi:9606">patients</span>
###xml 576 584 <span type="species:ncbi:9606">patients</span>
Our study shows that, out of 55 patients with bronchiectasis of unknown origin, 8 patients carried at least one missense mutation in ENaCbeta or ENaCgamma genes. Interestingly, the p.Ser82Pro mutation was found in 3 patients heterozygous for a CFTR mutation or variant. Functional tests to investigate the rate of sodium transport in the sweat glands or in the nasal epithelium were not contributive in suspecting the presence of these mutations since 3 patients out of the 8 patients bearing one ENaC mutation had a normal sweat test and a normal basal PD. However, in the 5 patients with abnormal functional tests bearing one ENaC mutation, the effect of the mutation on ENaC function might be hypothesized.
###end p 53
###begin p 54
###xml 338 339 331 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 340 342 333 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 420 436 413 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC&#945;, &#946; </italic>
###xml 440 445 426 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#947;</italic>
###xml 528 538 510 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC&#945; </italic>
###xml 542 547 520 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946; </italic>
###xml 732 734 707 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 890 892 865 867 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1219 1228 1194 1200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC&#946; </italic>
###xml 1232 1238 1204 1206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#947; </italic>
###xml 689 697 <span type="species:ncbi:9606">patients</span>
###xml 848 856 <span type="species:ncbi:9606">patients</span>
###xml 1114 1122 <span type="species:ncbi:9606">patients</span>
Liddle's syndrome is caused by nonsense, and frameshift mutations resulting mostly in truncation of carboxyl termini of beta and gammasubunits, and by missense mutations primarily located in a conserved PY motif (PPPXYXXL motif, codon 611 to 623). This leads to defective regulation of ENaC expression and activity, and gain-of-function [5,21]. PHA-I is mostly caused by nonsense, splice and frameshift mutations in the ENaCalpha, beta and gammagenes which produce truncated nonfunctional proteins, or missense mutations in the ENaCalpha and beta genes that decrease ENaC trafficking to the cell surface. All these mutations cause loss-of-function of the ENaC protein and were reported in patients with a severe phenotype of PHA-I [22]. In contrast, out of 22 mutations causing PHA-I, only 3 were missense mutations and they were reported in PHA-I patients with a mild form of the disease [22]. While the non-missense mutations lead to absence of normal-length protein, missense mutations allow the synthesis of a normal-length subunit that is more likely to support a residual channel activity. In this study, 55 patients with bronchiectasis of unknown origin have been examined for mutations in coding regions of the ENaCbeta and gamma genes and 5 different missense mutations were identified. It can by hypothesized that the missense mutation resulting from the nucleotide substitution allowed normal sodium reabsorption in the kydneys (therefore avoiding the syndromes of pseudohypoaldosteronism or pseudoaldosteronism seen in PHA-I and Liddle's syndrome); but this missense mutation might mildly affect ENaC function in the airway epithelium, and this abnormal ENaC protein would modify the extent of sodium absorption and lead to airway disease and bronchiectasis.
###end p 54
###begin p 55
###xml 215 225 215 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC&#946;) </italic>
###xml 347 349 344 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 437 439 434 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 440 442 437 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 587 592 584 589 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 603 605 600 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 785 794 782 791 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro </italic>
###xml 1207 1209 1204 1206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1390 1392 1387 1389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1479 1484 1476 1481 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC </italic>
###xml 1841 1843 1838 1840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1873 1878 1870 1875 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC </italic>
###xml 2560 2562 2557 2559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 2602 2607 2599 2604 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC </italic>
###xml 48 56 <span type="species:ncbi:9606">patients</span>
###xml 558 566 <span type="species:ncbi:9606">patients</span>
###xml 809 823 <span type="species:ncbi:8355">Xenopus laevis</span>
###xml 1446 1454 <span type="species:ncbi:9606">patients</span>
###xml 1552 1560 <span type="species:ncbi:9606">patients</span>
###xml 2376 2383 <span type="species:ncbi:9606">patient</span>
###xml 2550 2558 <span type="species:ncbi:9606">patients</span>
###xml 2627 2635 <span type="species:ncbi:9606">patients</span>
Four of the missense mutations were detected in patients with functional abnormalities suggesting impaired sodium transport in the sweat glands or in the nasal epithelium : two variants (p.Pro369Thr, p.Asn288Ser in ENaCbeta) were detected in this study for the first time and the other two (p.Ser82Cys and p.Gly183Ser) have been described before [13]. These variants have not been previously found in normal subjects in several studies [22-24] and were not detected in our ethnically-matched control group and in a "control" population of 56 cystic fibrosis patients with two pathogenic CFTR mutations [17]. They are therefore unlikely to be common polymorphisms. These variants were each found at the heterozygous state and the deleterious effect of this finding might be questioned. In vitro studies in the Xenopus laevis oocyte expression system could be performed to evaluate the precise effect of the new mutations we have found on ENaC structure and function. However, we did not performe these studies because it is thought that this system is not sensitive enough to detect little changes in ENaC activity and that only mutations leading to large changes in ENaC activity are liable to be detected [25]. Moreover, it is not known whether amphibian cells such as Xenopus oocytes possess the whole cellular machinery involved in the complex regulation of the ENaC in mammalian cells [26]. However, the functional abnormalities found in the patients speak for a role of the ENaC mutation in the pathophysiology of their airway disease. Hence, the patients bearing the p.Pro369Thr and p.Gly183Ser mutations had normal sweat chloride concentration (22 and 7 mmol/L, respectively) and a high basal PD (- 43 and - 39 mV, respectively) showing elevated nasal sodium transport. This pattern is similar to that described in Liddle's syndrome [10]. Indeed, in the presence of ENaC gain-of-function mutations such as in Liddle's syndrome, the sodium and chloride reabsorption in the sweat duct are normal leading to normal sweat chloride concentrations. In contrast, there is an increased sodium reabsorption in the airway epithelium causing an increased nasal PD. Therefore, the functional pattern we observed for sodium transport in the sweat gland and in the airway epithelium suggests that p.Pro369Thr and p.Gly183Ser are mutations causing a gain of ENaC function. As for the patient bearing the p.Asn288Ser mutation, she had high sweat chloride concentration (57 mmol/L) with low basal nasal PD (- 10 mV), displaying the pattern described for PHA-I patients [12]. In loss-of-function mutations in the ENaC gene as seen in PHA patients, the defective ENaC causes defective sodium and chloride reabsorption in the sweat duct and elevated sweat chloride and sodium concentrations. In the airways, the low sodium reabsorption leads to a low basal nasal PD. Therefore, the functional pattern we observed for the p.Asn288Ser mutation suggests it to be a loss-of-function mutation.
###end p 55
###begin p 56
###xml 416 418 416 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 446 451 446 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC </italic>
###xml 655 657 655 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 729 734 729 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 774 779 774 779 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 910 915 910 915 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC </italic>
###xml 1031 1036 1031 1036 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 1047 1049 1047 1049 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1082 1087 1082 1087 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC </italic>
###xml 1140 1145 1140 1145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 1230 1232 1230 1232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1327 1341 1327 1338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC&#946;/CFTR </italic>
###xml 1606 1611 1603 1608 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC </italic>
###xml 1617 1619 1614 1616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1696 1710 1693 1704 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC&#946;/CFTR </italic>
###xml 194 202 <span type="species:ncbi:9606">patients</span>
###xml 406 414 <span type="species:ncbi:9606">patients</span>
###xml 429 437 <span type="species:ncbi:9606">patients</span>
###xml 685 693 <span type="species:ncbi:9606">patients</span>
###xml 803 810 <span type="species:ncbi:9606">patient</span>
###xml 883 891 <span type="species:ncbi:9606">patients</span>
###xml 999 1007 <span type="species:ncbi:9606">patients</span>
###xml 1189 1197 <span type="species:ncbi:9606">patients</span>
###xml 1266 1274 <span type="species:ncbi:9606">patients</span>
The p.Ser82Cys mutation was relatively common in our population (3/55; 5.4%) and was found in both groups, with or without functional abnormalities suggesting impaired sodium transport. The two patients from Group 1 bearing the p.Ser82Cys mutation had rather high sweat chloride concentrations (44 and 38 mmol/L) with rather low basal nasal PD (- 13 and - 8 mV), displaying the pattern described for PHA-I patients [12], that is patients bearing ENaC mutations causing a loss of function in the ENaC channel. However, this p.Ser82Cys mutation has been reported at a frequency of 2% in control subjects, thus making its mere presence deleterious doubtful [27]. Interestingly, the three patients bearing this variant also bore one CFTR mutation (p.F508del in one case) or one CFTR variant (IVS8-5T in one patient, and IVS8-5T-1716G>A in the other), which was not the case for the four patients bearing one other ENaC mutation. This p.Ser82Cys variant was not found in our cohort of 56 cystic fibrosis patients bearing two pathogenic CFTR mutations [17]. To date, a combination of one ENaC mutation, including this p.Ser82Cys mutation, plus a CFTR mutation, has been occasionally reported in patients with idiopathic bronchiectasis [27]. Here, we have identified three patients with bronchiectasis who are trans-heterozygotes for ENaCbeta/CFTR mutations or variants, and these cases strongly suggest an interaction between different susceptibility factors in the pathogenesis of their airway disease. As it has been previously suggested in sporadic cases of PHA-I with various polymorphisms identified in the ENaC gene [21], this sporadic presentation of bronchiectasis with trans-heterozygotie for ENaCbeta/CFTR mutations could be the result of digenic or multigenic expression and complex hereditary transmission.
###end p 56
###begin p 57
###xml 54 69 54 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC&#946; &#947; </italic>
###xml 232 237 225 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC </italic>
###xml 402 407 395 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 460 470 453 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC&#947; </italic>
###xml 572 577 561 566 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC </italic>
###xml 810 815 799 804 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC </italic>
###xml 1083 1085 1072 1074 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 12 20 <span type="species:ncbi:9606">patients</span>
###xml 331 339 <span type="species:ncbi:9606">patients</span>
###xml 380 387 <span type="species:ncbi:9606">patient</span>
###xml 526 534 <span type="species:ncbi:9606">patients</span>
Among the 8 patients bearing one missense mutation in ENaCbeta gamma gene, 3 had functional tests suggesting normal sodium transport in the sweat glands and in the nasal epithelium. This, together with the heterozygous state of the ENaC mutation, may suggest that this mutation does not play a role in the pathophysiology of these patients' airway disease. However, as one of the patient bore also one CFTR variant (IVS8-5T) and as the other two bore the same ENaCgamma mutation (p.Glu197Lys) and were among the most affected patients of the group, the implication of the ENaC mutation can not be ruled out. If the last hypothesis is true, our results indicate that the functional tests studying sodium transport, such as sweat testing and nasal PD, are not always contributive in suspecting a mutation in the ENaC gene. Moreover, it strengthens our hypothesis that airway disease related to partly defective ENaC protein might be the result of complex susceptibility factors and this is all the more emphasized by the growing knowledge of all the accessory factors regulating ENaC [28].
###end p 57
###begin p 58
###xml 111 120 111 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENaC&#946; </italic>
###xml 123 129 120 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#947; </italic>
###xml 376 381 369 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 17 25 <span type="species:ncbi:9606">patients</span>
###xml 74 82 <span type="species:ncbi:9606">patients</span>
###xml 285 293 <span type="species:ncbi:9606">patients</span>
In a group of 55 patients with idiopathic bronchiectasis, we identified 8 patients bearing one mutation in the ENaCbeta or gamma genes. Although the significance of these findings at the functional level requires further investigation, a defective ENaC protein may be involved in some patients with idiopathic bronchiectasis or cystic fibrosis-like lung disease with only one CFTR mutation identified.
###end p 58
###begin title 59
Competing interests
###end title 59
###begin p 60
The authors declare that they have no competing interests.
###end p 60
###begin title 61
Authors' contributions
###end title 61
###begin p 62
IF, DH and TB designed the study, MV and SS performed the genetic analysis, IF performed the nasal PD measurements. All authors have participated in the analyses of data. IF and TB had the major responsibility for drafting the manuscript. All authors read and approved the final manuscript.
###end p 62
###begin title 63
Aknowledgements
###end title 63
###begin p 64
###xml 545 553 <span type="species:ncbi:9606">patients</span>
The authors are indebted to Prof. M. Aubier (Bichat Hospital, Paris), Dr L. Bassinet (Centre Hospitalier Intercommunal de Creteil), Dr P.R. Burgel (Cochin Hospital, Paris), Prof J. Cadranel (Tenon Hospital, Paris), Prof. L.J. Couderc (Foch Hospital, Suresnes), Prof. B. Crestani (Bichat Hospital, Paris), Dr N. Dufeu (Cochin Hospital, Paris), Prof. D. Dusser (Cochin Hospital, Paris), Dr I. Honore (Centre Hospitalier Intercommunal de Creteil), Dr J. Lacronique (Cochin Hospital, Paris), Dr E. Rivaud (Foch Hospital, Suresnes) for referring the patients. This work was supported by a grant from the association Vaincre la Mucoviscidose.
###end p 64
###begin article-title 65
###xml 43 51 <span type="species:ncbi:9606">patients</span>
An investigation into causative factors in patients with bronchiectasis
###end article-title 65
###begin article-title 66
Number of subunits comprising the epithelial sodium channel
###end article-title 66
###begin article-title 67
Determination of epithelial Na+ channel subunit stoichiometry from single-channel conductances
###end article-title 67
###begin article-title 68
Cystic fibrosis transmembrane conductance regulator inverts protein kinase A-mediated regulation of epithelial sodium channel single channel kinetics
###end article-title 68
###begin article-title 69
A de novo missense mutation of the b subunit of the epithelial sodium channel causes hypertension and Liddle syndrome, identifying a proline-rich segment critical for regulation of channel activity
###end article-title 69
###begin article-title 70
Mutations in subunits of the epithelial sodium channel cause salt wasting with hyperkaliemic conditions acidosis, pseudohypoaldosteronism type 1
###end article-title 70
###begin article-title 71
###xml 63 72 63 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#945;ENaC</italic>
###xml 83 87 <span type="species:ncbi:10090">mice</span>
Early death due to defective neonatal lung liquid clearance in alphaENaC-deficient mice
###end article-title 71
###begin article-title 72
###xml 89 93 <span type="species:ncbi:10090">mice</span>
Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice
###end article-title 72
###begin article-title 73
New concepts of the pathogenesis of cystic fibrosis lung disease
###end article-title 73
###begin article-title 74
Abnormalities of nasal potential difference measurements in Liddle's syndrome
###end article-title 74
###begin article-title 75
Pseudohypoaldosteronism with increased sweat and saliva electrolyte values and frequent lower respiratory tract infections mimicking cystic fibrosis
###end article-title 75
###begin article-title 76
Pulmonary epithelial sodium-channel dysfunction and excess airway liquid in pseudohypoaldosteronism
###end article-title 76
###begin article-title 77
###xml 63 71 <span type="species:ncbi:9606">patients</span>
Mutations in the beta subunit of the epithelial Na+ channel in patients with a cystic fibrosis-like syndrome
###end article-title 77
###begin article-title 78
CT of airway disease and bronchiectasis
###end article-title 78
###begin article-title 79
In vivo nasal potential difference: techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis
###end article-title 79
###begin article-title 80
Diagnostic sweat testing : the cystic fibrosis foundation guidelines
###end article-title 80
###begin article-title 81
ENaCbeta and gamma genes as modifier genes in cystic fibrosis
###end article-title 81
###begin article-title 82
Website title
###end article-title 82
###begin article-title 83
Website title
###end article-title 83
###begin article-title 84
Website title
###end article-title 84
###begin article-title 85
Liddle's syndrome caused by a novel mutation in the proline-rich PY motif of the epithelial sodium channel beta-unit
###end article-title 85
###begin article-title 86
Novel mutations in epithelial sodium channel (ENaC) subunit genes and phenotypic expression of multisystem pseudohypoaldosteronism
###end article-title 86
###begin article-title 87
Polymorphisms of amiloride-sensitive sodium channel subunits in five sporadic cases of pseudohypoaldosteronism: Do they have pathologic potential?
###end article-title 87
###begin article-title 88
Novel mutations responsible for autosomal recessive multisystem pseudohypoaldosteronism and sequence variants in epithelial sodium channel alpha-, beta-, and gamma-subunits genes
###end article-title 88
###begin article-title 89
Common variants of the beta and gamma subunits of the epithelial sodium channel and their relation to plasma renin and aldosterone levels in essential hypertension
###end article-title 89
###begin article-title 90
Genetic analysis of the beta subunit of the epithelial Na+ channel in essential hypertension
###end article-title 90
###begin article-title 91
###xml 29 37 <span type="species:ncbi:9606">patients</span>
The involvment of ENaC in CF patients in whom a mutation cannot be identified on both CFTR genes [abstract]
###end article-title 91
###begin article-title 92
Accessory factors and the regulation of epithelial sodium channel activity
###end article-title 92

